• News
  • SAN DIEGO
  • BioTech

Ambit Biosciences falls on slower path for drug

Shares of Ambit Biosciences tumbled Wednesday after the company said it won't file for accelerated approval of its leukemia drug quizartinib, and will run a late-stage clinical trial instead.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!